Emmanuel Papadakis

Stock Analyst at Deutsche Bank

(0.94)

# 2,759

Out of 4,413 analysts

28

Total ratings

52.94%

Success rate

-2.12%

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General Biotechnology Drug Manufacturers - Specialty & Generic

11 Stocks

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	GRFS Grifols	Downgrades: Sell	n/a	$6.79	-	2	Mar 12, 2024
	AZN AstraZeneca	Downgrades: Hold	n/a	$76.41	-	2	Feb 8, 2024
	MRNA Moderna	Downgrades: Sell	n/a	$111.46	-	6	Nov 2, 2023
	BNTX BioNTech SE	Maintains: Hold	$135 → $120	$89.95	+33.41%	6	May 18, 2023
	ALVO Alvotech	Maintains: Hold	$8 → $12	$14.48	-17.13%	2	Mar 7, 2023
	SNY Sanofi	Upgrades: Hold	n/a	$50.03	-	2	Aug 12, 2022
	NVO Novo Nordisk	Upgrades: Buy	n/a	$129.21	-	2	Mar 16, 2022
	NVS Novartis AG	Downgrades: Sell	n/a	$97.50	-	2	Sep 20, 2021
	ARGX argenx SE	Initiates: Hold	n/a	$383.34	-	1	Jul 23, 2021
	RHHBY Roche Holding AG	Upgrades: Buy	n/a	$29.75	-	1	Jul 8, 2021
	GSK GSK	Downgrades: Sell	n/a	$42.57	-	2	Feb 4, 2021

Grifols

Mar 12, 2024

Downgrades: Sell

Price Target: n/a

Current: $6.79

Upside: -

AstraZeneca

Feb 8, 2024

Downgrades: Hold

Price Target: n/a

Current: $76.41

Upside: -

Moderna

Nov 2, 2023

Downgrades: Sell

Price Target: n/a

Current: $111.46

Upside: -

BioNTech SE

May 18, 2023

Maintains: Hold

Price Target: $135 → $120

Current: $89.95

Upside: +33.41%

Alvotech

Mar 7, 2023

Maintains: Hold

Price Target: $8 → $12

Current: $14.48

Upside: -17.13%

Sanofi

Aug 12, 2022

Upgrades: Hold

Price Target: n/a

Current: $50.03

Upside: -

Novo Nordisk

Mar 16, 2022

Upgrades: Buy

Price Target: n/a

Current: $129.21

Upside: -

Novartis AG

Sep 20, 2021

Downgrades: Sell

Price Target: n/a

Current: $97.50

Upside: -

argenx SE

Jul 23, 2021

Initiates: Hold

Price Target: n/a

Current: $383.34

Upside: -

Roche Holding AG

Jul 8, 2021

Upgrades: Buy

Price Target: n/a

Current: $29.75

Upside: -

GSK

Feb 4, 2021

Downgrades: Sell

Price Target: n/a

Current: $42.57

Upside: -